Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)
Status:
Completed
Trial end date:
2016-03-06
Target enrollment:
Participant gender:
Summary
The goal of this study is to start treatment with the NOTCH1 inhibitor brontictuzumab in an
attempt to control tumors and prolong survival. The therapy involves participant being given
the drug brontictuzumab to treat adenoid cystic carcinoma (ACC) with NOTCH 1 mutations. This
is considered an investigational treatment.